Guidelines for preclinical and early phase clinical assessment of novel radiosensitisers.
Guidelines for preclinical and early phase clinical assessment of novel radiosensitisers.
复制标题
DOI：
10.1038/bjc.2011.240
复制
发表时间：
2011-08-23
影响因子：
8.8
通讯作者：
Illidge T
中科院分区：
文献类型：
--
作者：
Harrington KJ;Billingham LJ;Brunner TB;Burnet NG;Chan CS;Hoskin P;Mackay RI;Maughan TS;Macdougall J;McKenna WG;Nutting CM;Oliver A;Plummer R;Stratford IJ;Illidge T
越来越多的人认识到新型分子靶向药物与放射治疗或放化疗相结合的潜在价值。这种方法有可能改善局部疾病控制和各种肿瘤类型的治愈率。在这份报告中，我们概述了一个合理的框架，开发新的药物辐射组合。在此过程中，我们就作为人体研究理由所需的核心临床前数据集提出建议，并描述研究者可能采用的潜在临床试验设计。
There is a growing appreciation of the potential value of combining novel molecularly-targeted drugs with radiotherapy or chemoradiotherapy. Such approaches have the potential to improve locoregional disease control and cure rates across a diverse range of tumour types. In this report, we outline a rational framework for developing novel drug–radiation combinations. In doing so, we make recommendations regarding the core preclinical data sets that are required to serve as justification for studies in humans and describe potential clinical trial designs that may be adopted by investigators.